Next: Identify Causes & Treatments →

Diagnostic Procedures for Azoospermia

Needle biopsy, FNA mapping, ultrasound, and the new wave of non-invasive cfDNA / RNA tests.

Last updated: May 2026 Reading time: ~8 min Step: 5 of 14

Key Takeaways

  • Needle biopsy is the first diagnostic procedure most men consider — it confirms OA vs NOA before any larger surgery.
  • FNA mapping finds sperm in ~25% of NOA men non-surgically. Useful, but if negative you still have a 1-in-3 chance of success at microTESE.
  • NOA Guide (cfDNA) is a $525 non-invasive test that estimates microTESE success likelihood.
  • RNA-based testing is promising research but not yet commercially available.

Current Diagnostic Procedures

Needle Biopsy

A needle biopsy involves inserting a needle into the testicle to determine whether you have obstructive or non-obstructive azoospermia. This procedure can be performed in an outpatient setting or immediately before sperm retrieval surgery.

Primary Purpose

To ensure you don't undergo more invasive surgery than necessary. If the needle biopsy confirms obstructive azoospermia, your testicles won't need to be surgically opened as they would for non-obstructive azoospermia treatment.

Testicular Biopsy (Not Recommended)

This procedure involves surgically cutting a portion of the testicle's periphery. These biopsies are generally not recommended and rarely performed because they provide little diagnostic value while causing unnecessary harm to the testicle.

FNA Mapping (Fine Needle Aspiration Mapping)

FNA mapping is an outpatient procedure that systematically samples different areas of the testicle to locate sperm. The process involves multiple needle insertions through the testicle (surprisingly painless and minimally harmful), with each sample analyzed extensively.

The theory: If sperm is found, doctors know which testicle and specific location contains sperm, potentially guiding future surgical retrieval.

Important Limitations of FNA Mapping

Success rate comparison:

  • FNA mapping finds sperm in approximately 25% of men
  • MicroTESE surgery finds sperm in approximately 50% of men
The math If FNA mapping is negative, you still have a 1 in 3 chance of finding sperm during microTESE.

Decision points:

  • FNA mapping can be considered an extra, unnecessary step before microTESE
  • FNA mapping likely only makes sense if you're comfortable with lower accuracy and would choose not to proceed to surgery if results are negative
  • FNA mapping is easily recoverable and doesn't cause the long-term damage that microTESE can

Doctors Performing FNA Mapping

Ultrasound

Some doctors perform testicular or transrectal ultrasounds for several purposes:

Testicular Ultrasound

  • Measure testicle size accurately
  • Check for varicoceles (enlarged veins)
  • Identify obstructions, tumors, or other testicular issues

Transrectal Ultrasound

  • Examine internal reproductive structures
  • Should only be recommended if results will genuinely change treatment approach

Research-Based Diagnostics (Experimental)

Hormone Prediction Models

Extensive research has attempted to predict sperm retrieval success based on hormone levels. Unfortunately, no hormone markers reliably predict successful sperm retrieval surgeries.

Cell-Free DNA (cfDNA) Testing — NOA Guide

Even when no sperm are visible in a semen sample, tiny fragments of DNA are still present in the seminal fluid. Some of these fragments originate from sperm cells within the testes. NOA Guide, developed by Path Fertility (a brand of Inherent Biosciences), is a commercially available test that analyzes this cell-free DNA (cfDNA) and looks for DNA methylation patterns unique to sperm.[3] These patterns act like a biological fingerprint, allowing sperm-derived DNA to be distinguished from DNA coming from other cell types.

By measuring the proportion of sperm-derived DNA in your sample, NOA Guide estimates the likelihood of finding sperm during surgical retrieval (e.g., microTESE).[1][2] Your result places you into one of three groups — High, Moderate, or Low success — based on outcomes observed in prior patients with similar results. Men in the High success category had nearly 12x higher odds of retrieval than those in the Low category.[1]

The process is non-invasive: your doctor orders the test, a collection kit is mailed to your home, and results are returned to your doctor within approximately two weeks. The test costs $525 (cash pay; pricing may vary with insurance or employer benefits). NOA Guide does not diagnose the cause of azoospermia or guarantee surgical outcomes — it is one additional piece of information to support decision-making alongside your hormones, genetics, imaging, and clinical evaluation.

RNA Testing

Researchers are also exploring various RNA molecules in semen as non-invasive predictors of sperm retrieval success. Unlike cfDNA testing, RNA-based testing is not yet commercially available, but several promising biomarker classes have been studied:[4]

  • Cell-free seminal RNA (cfRNA): A 2024 study from Weill Cornell Medicine combined DNA sequencing of surgically retrieved sperm with RNA sequencing of cell-free RNA in seminal fluid from men with NOA. The transcriptomic profile was able to predict residual spermatogenic foci and help anticipate sperm retrieval at testicular biopsy.[5] Follow-up multi-omics work from the same group (2024 and 2025) narrowed in on two specific genes — TPTE2 (a testis-specific spermatogenesis regulator) and NEU1 (involved in acrosome development) — whose expression patterns in seminal plasma correctly separated men who had sperm found at micro-TESE from those who did not in their cohorts.[6][7]
  • MicroRNAs (miRNAs): Small non-coding RNAs in seminal plasma that regulate spermatogenesis. Studies have built predictive models using specific miRNA panels combined with machine learning to estimate the likelihood of finding sperm at microTESE.[8]
  • tRNA-derived small RNAs (tsRNAs): A specific tsRNA called tRF-Val-AAC-010, found in seminal plasma extracellular vesicles, predicted successful microTESE retrieval with ~89% accuracy (AUC 0.89, 72% sensitivity, 91% specificity) in one study.[9]
  • Circular RNAs (circRNAs): Levels of circ_MGLL in testicular tissue correlate inversely with retrieval success. A nomogram combining circ_MGLL with FSH, LH, and testosterone reached an AUC of 0.857 for predicting successful retrieval in idiopathic NOA.[10]

While these results are promising, the evidence base is still small and most studies have not been independently replicated. Larger, multi-center trials are needed before any RNA-based test can be recommended clinically.[4]

High-Frequency Ultrasound

Advanced ultrasound technology can measure tubule sizes within testicles. Some studies have tried to predict microTESE success using these detailed measurements, though this remains experimental.

Frequently Asked Questions

What is FNA mapping?

A non-surgical, office-based procedure that systematically samples many specific locations across the testicle to map where sperm production exists. Pioneered by Dr. Paul Turek. Finds sperm in ~25% of NOA men.

What is the NOA Guide test?

NOA Guide is a non-invasive test from Path Fertility that analyzes cell-free DNA in seminal fluid to estimate the chance of finding sperm at microTESE. Uses sperm-specific DNA methylation patterns. Costs $525 cash pay.

Can RNA from semen predict sperm retrieval success?

Research from Weill Cornell and others suggests cell-free RNA, microRNAs, tsRNAs, and circRNAs in semen may help predict microTESE outcomes. None are commercially available yet — this is still research.

Is FNA mapping a good idea before microTESE?

Maybe. If FNA finds sperm, that's wonderful news. But if it doesn't, you still have ~1-in-3 odds of success at microTESE. So FNA mapping mostly makes sense if you'd choose to skip surgery on a negative result.

← Previous: Determine Your Type Next: Identify Causes & Treatments →

References

  1. Olesen et al. A non-invasive assay for predicting sperm retrieval outcomes and identifying Klinefelter's syndrome in men with non-obstructive azoospermia using single-molecule native methylation sequencing of sperm-specific cell-free DNA. American Society for Reproductive Medicine Annual Meeting; Fertility and Sterility, Vol. 124, Issue 6, e112, December 2025.
  2. Olesen et al. A non-invasive predictor of sperm retrieval success in men with non-obstructive azoospermia using single-molecule native methylation sequencing of sperm-specific cell-free DNA. American Urological Association Annual Meeting; Journal of Urology, May 2025.
  3. Salameh et al. Tissue-specific DNA methylation variability and its potential clinical value. Frontiers in Genetics, Vol. 14, 2023.
  4. Hu et al. Seminal plasma biomarkers for predicting successful sperm retrieval in patients with nonobstructive azoospermia: a narrative review of human studies. Basic and Clinical Andrology, 2023.
  5. Cheung, Ng, Xie, Kocur, Elias, Schlegel, Rosenwaks, Palermo. Genetic profiling of azoospermic men to identify the etiology and predict reproductive potential. Weill Cornell Medicine. Journal of Assisted Reproduction and Genetics, February 2024.
  6. Ng, Cheung, Xie, Rosenwaks, Palermo. Predicting success of testicular sperm retrieval through multi-omics analysis of cell-free seminal plasma in NOA men. Weill Cornell Medicine. Fertility and Sterility, Vol. 122, Issue 4, Supplement e123, October 2024.
  7. Ng, Cheung, Xie, Rosenwaks, Palermo. Predicting residual spermatogenesis by a non-invasive multi-omics panel on the seminal plasma of NOA men. Weill Cornell Medicine. Fertility and Sterility, Vol. 124, Issue 6, Supplement e112, December 2025.
  8. Zhang et al. Circulating microRNAs in seminal plasma as predictors of sperm retrieval in microdissection testicular sperm extraction. Annals of Translational Medicine.
  9. Chen et al. Seminal plasma extracellular vesicles tRF-Val-AAC-010 can serve as a predictive factor of successful microdissection testicular sperm extraction in patients with non-obstructive azoospermia. Reproductive Biology and Endocrinology, 2022.
  10. Lv et al. Nomogram based on a circular RNA biomarker for predicting the likelihood of successful sperm retrieval via microdissection testicular sperm extraction in patients with idiopathic non-obstructive azoospermia. Frontiers in Endocrinology, 2022.